Lancet. 2011 Mar 12;377(9769):878-80. doi: 10.1016/S0140-6736(11)60280-8. Epub 2011 Mar 2.

EMBRACE, eribulin, and new realities of advanced breast cancer.

Lin NU, Burstein HJ.

Source

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

Comment on

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. [Lancet. 2011]
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al. Lancet. 2011 Mar 12; 377(9769):914-23. Epub 2011 Mar 2.

PMID:: 21376386; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. [Lancet. 2011]
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al. Lancet. 2011 Mar 12; 377(9769):914-23. Epub 2011 Mar 2.
Eribulin mesylate. [Nat Rev Drug Discov. 2011]
Eribulin mesylate.
Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. Nat Rev Drug Discov. 2011 Mar; 10(3):173-4.
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. [Future Oncol. 2011]
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J, Lorca R. Future Oncol. 2011 Mar; 7(3):355-64. Epub 2011 Mar 7.
Review Eribulin. [Drugs. 2011]
Review Eribulin.
Perry CM. Drugs. 2011 Jul 9; 71(10):1321-31.
Review Eribulin mesylate for the treatment of breast cancer. [Expert Opin Pharmacother. 2010]
Review Eribulin mesylate for the treatment of breast cancer.
Cigler T, Vahdat LT. Expert Opin Pharmacother. 2010 Jun; 11(9):1587-93.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

EMBRACE, eribulin, and new realities of advanced breast cancer.
EMBRACE, eribulin, and new realities of advanced breast cancer.
Lancet. 2011 Mar 12 ;377(9769):878-80. doi: 10.1016/S0140-6736(11)60280-8. Epub 2011 Mar 2 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: